<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="474">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347954</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-56134</org_study_id>
    <nct_id>NCT04347954</nct_id>
  </id_info>
  <brief_title>PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)</brief_title>
  <official_title>Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing
      nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The
      primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In
      vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS
      and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated
      in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the
      incidence and symptoms of viruses which cause the &quot;common cold.&quot;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in viral titers of SARS-CoV-2</measure>
    <time_frame>Day 1 (baseline), Day 1 (4 hours), Day 5</time_frame>
    <description>Nasopharyngeal swabs will be obtained and quantitative polymerase chain reaction (PCR) testing will be performed to determine the viral load in the nasopharynx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse effects of interest after nasal sprays</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Adverse effects of interest include:
Nasal burning/pain
Headaches
Ear pain
Sneezing
Nose bleeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of symptoms related to SARS-CoV-2</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Symptoms of interest include:
Fever
Fatigue
Change in smell
Change in taste
Nasal obstruction
Chills
Sore throat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with study drug administration</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Self report by participants (survey) of estimated doses completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>Day 1 (baseline), Day 30</time_frame>
    <description>Participants scratch the cards and attempt to identify the smell from a multiple choice set of options. Their scores are then computed and categorized as normal, mild, moderate, or severe microsmia (loss of smell).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Povidone-Iodine 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.
Participants will complete a daily symptom journal from Day 1 through Day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Povidone-Iodine 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.
Participants will complete a daily symptom journal from Day 1 through Day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic saline 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.
Participants will complete a daily symptom journal from Day 1 through Day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine 2%</intervention_name>
    <description>Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day</description>
    <arm_group_label>Povidone-Iodine 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine 0.5%</intervention_name>
    <description>Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day</description>
    <arm_group_label>Povidone-Iodine 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline 0.9%</intervention_name>
    <description>Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day</description>
    <arm_group_label>Isotonic saline 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COVID-19 by lab test within 5 days of study participation

        Exclusion Criteria:

          -  Allergy to &quot;iodine,&quot; shellfish, or food dye

          -  Receiving intranasal steroids

          -  Sinus surgery within 30 days of beginning the study

          -  Intubated at the time of enrollment

          -  Pregnancy

          -  Participation in other COVID-19 studies - to be determined on a case by case basis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayakar V. Nayak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neelaysh Vukkadala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Team</last_name>
      <phone>650-725-6500</phone>
      <email>covid19study@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasal spray</keyword>
  <keyword>PVP-I</keyword>
  <keyword>COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

